ClinicalTrials.gg
RecruitingNCT06994676CROSSCHECK-001Updated Mar 16, 2026

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

A Phase 1 interventional study of CBX-250 in High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML) and AML - Acute Myeloid Leukemia, sponsored by Crossbow Therapeutics, Inc.. Recruiting at 11 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Crossbow Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 441 studies in Leukemia, Myelomonocytic, Chronic with a site in United States — 47 open to participants now, 80 under way, 3 of them phase 3. Leukemia, Myelomonocytic, Chronic · United States.

Planned enrollment
101st of 370
72 · median 37
Started
2025
with 9 others
Phase 1
143 of 441
16 open now
Primary completion
2027-01
later than 28 of 79 live
Registered
432nd of 441
by date

Among the 441 studies in Leukemia, Myelomonocytic, Chronic with a site in United States, this one is the 101st largest by planned enrollment of the 370 interventional ones that give a count, is one of 10 that started in 2025, is one of 143 in phase 1, reaches primary completion later than 28 of the 79 other live ones, and was the 432nd registered.

Leukemia, Myelomonocytic, Chronic

540 studies on the registry are indexed under Leukemia, Myelomonocytic, Chronic; 68 are open to participants now.

Browse Leukemia, Myelomonocytic, Chronic studies →

Open to participants now

47 of the 441 studies in Leukemia, Myelomonocytic, Chronic with a site in United States are open now. Recruiting first, the newest first:

41 more — sign in →

All 47 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 62 Leukemia, Myelomonocytic, Chronic studies recruiting now, 46 (74%) set no upper age limit and 7 (11%) stop at 75 or younger; 8 take children under 18; 4 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 441 studies in Leukemia, Myelomonocytic, Chronic with a site in United States, or all of them as a file.
02

Study summary

Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Participants aged ≥ 12 years are planned to be enrolled. CBX-250 will initially be investigated on a fixed step-up dosing schedule. CBX-250 will be administered subcutaneously in 28-day cycles, with the first study drug dose administered on Cycle 1, Day 1. Cycle 1 will consist of a priming phase over 7 days, and a target phase over 28 days. Participants will continue CBX-250 until progressive disease (PD) or unacceptable toxicity. All subsequent treatment cycles will be 28 days.

03

Conditions studied

  • High-risk Myelodysplastic Syndrome
  • Chronic Myelomonocytic Leukemia (CMML)
  • AML - Acute Myeloid Leukemia
  • Chronic Myeloid Leukemia

Keywords

  • AML
  • HR-MDS
  • CMML
  • acute leukemia
  • CBX-250
  • CBX-250-001
  • CROSSCHECK
  • CROSSCHECK-001
  • Crossbow
  • CML
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

Age

  1. Dose Escalation: Male or female participants aged ≥18 years.
  2. Backfill Cohorts: Male or female participants aged ≥12 years for whom no curative treatment options, including transplantation, are available.

    Diagnosis \& Disease Characteristics

  3. Participants with histological confirmation of advanced hematologic including:

    1. R/R AML, as defined by standardized criteria (e.g., European LeukemiaNet criteria [Dohner 2022]; after standard of care therapy. Participants with persistent leukemia after initial therapy or with recurrence of leukemia at any time after achieving a response during or after the course of treatment (including ) are eligible.
    2. R/R HR-MDS or very high risk MDS as per the Revised International Prognostic Scoring System (IPSS-R; Greenberg 2012) or Molecular International Prognostic Scoring System (IPPS-M, Bernard 2022) who are resistant or to 4-6 cycles of hypomethylating agents (HMA; decitabine or azacitidine).
    3. R/R CMML who are resistant or refractory to 4-6 cycles of hypomethylating agents (HMA; decitabine or azacitidine).
  4. White blood cells must be below 25,000/µL at time of enrollment. Participants may receive cytoreduction prior to enrollment.
  5. Historical documented evidence of HLA-A*02:01 allele positivity.

    Performance Level

  6. PS score 0-1 (if aged ≥18 years); Performance Scale of ≥70 (if aged ≥16 years and \<18 years); Lansky PS of ≥70 (if aged \<16 years).

    Prior Therapy

  7. Any prior treatment-related toxicities resolved to ≤Grade 1 prior to enrollment, with the exception of ≤Grade 2 alopecia.
  8. Radiation Therapy: At least 60 days from prior total body irradiation, craniospinal radiation and/or ≥50% radiation of the pelvis, or at least 14 days from local palliative radiation therapy (small port).
  9. Stem Cell Infusion: At least 60 days must have elapsed from HSCT and at least 4 weeks (from first dose) must have elapsed from donor lymphocyte infusion without conditioning.
  10. Immunotherapy: At least 42 days since prior immunotherapy, including tumor vaccines and , and at least 21 days since receipt of chimeric antigen receptor therapy.
  11. Anti-Leukemia Therapy: At least 14 days since the completion of anti-leukemic therapy (for example, but not limited to, small molecule or cytotoxic/myelosuppressive therapy), with the following exceptions:

    • Hydroxyurea for cytoreduction can be initiated without restriction related to timing of study entry. Hydroxyurea for cytoreduction can be continued concomitantly with CBX-250, with Study Responsible Physician approval.
    • Intrathecal chemotherapy at the time of diagnostic lumbar puncture at least 24 hours prior to the start of CBX-250 and may continue prophylactic intrathecal chemotherapy beginning in Cycle 2, at the treating physician's discretion.
  12. Hematopoietic Growth Factors: At least 7 days since the completion of therapy with short-acting hematopoietic growth factors and 14 days with long-acting growth factors.
  13. Biologics (e.g. monoclonal antibody therapy): At least 28 days or 5 half-lives, whichever is shorter, have elapsed since the completion of therapy with a biologic agent. Any AE related to prior biologic treatment must be resolved to baseline severity or ≤Grade 1.
  14. : At least 7 days since systemic glucocorticoid therapy, unless receiving physiologic dosing (equivalent to ≤10 mg prednisone daily) or cytoreductive therapy. Cytoreductive therapy must have approval of the Study Responsible Physician.

    Adequate Organ Function Requirements within 10 Days of Treatment Initiation

  15. Estimated ≥ 45 mL/min/1.73 m2 based on local institutional practice for age-appropriate determination (eg, Schwartz formula for pediatric participants or formula for adults).

    1. Participants ≥18 years: glomerular filtration rate ≥45 mL/min
    2. Participants \<18 years: ≥45 mL/min x (participant's body surface area m2/1.73) • Adequate liver function defined as:

      • Total \<1.5 × the (ULN) for age or normal conjugated bilirubin, or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in participants with well documented Gilbert's syndrome or hemolysis or who require regular blood transfusions.
      • (ALT) and aspartate aminotransferase (AST) \<3 × ULN (unless attributed to leukemic involvement with discussion with the Study Responsible Physician).

    Sex and /Barrier Requirements

  16. If a female of , willing to use a highly effective method of contraception or double barrier method from the time of enrollment through 120 days following the last study drug dose.
  17. If male of childbearing potential, agrees to use barrier contraception from the time of enrollment through 120 days following the last study drug dose.

  18. Participant or participant's health care proxy is able and willing to provide written informed consent and able to follow study instructions.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

Diagnosis

  1. Previous CTSG targeted therapy or treatment with any pMHC T-cell engager.
  2. Isolated extramedullary relapse.
  3. Active central nervous system (CNS) disease. Participants with prior CNS history can be enrolled if the participant has a negative lumbar puncture following completion of intrathecal chemotherapy).

    Infection

  4. Known infection.
  5. Active infection (participants with documented clearance following treatment are allowed).
  6. Active infection (participants with documented clearance following treatment are allowed).

    Pregnancy and Breastfeeding

  7. Pregnant or nursing women: Negative serum pregnancy tests are required during Screening and a negative serum or urine pregnancy test is required within 72 hours prior to receiving the first study drug administration, in females of . If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

    Concurrent Conditions

  8. Cardiac Disease:

    • Any of the following within the 6 months prior to study entry: myocardial infarction, uncontrolled/unstable angina, congestive heart failure ( Classification Class >II), life-threatening, uncontrolled arrhythmia, cerebrovascular accident, or .
    • using Fridericia's correction (QTcF) >480 msec
  9. (GVHD): Active acute or chronic GVHD requiring systemic treatment with medication. Participants may be on physiological doses of .
  10. Concurrent in the previous 2 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ, melanoma in situ) treated with potentially curative therapy. Concurrent malignancy must be in CR or no evidence of disease (NED) during this timeframe.
  11. History of or any concurrent condition, therapy, or laboratory abnormality that in the Investigator's opinion might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate.

    Concomitant Medications and Interventions

  12. Any commercially available or anti-leukemic therapy other than CBX-250, with the following exceptions:

    • Intrathecal chemotherapy for CNS prophylaxis is permitted after C1 is complete, at the treating physician's discretion.
  13. Participation in another therapeutic interventional clinical study in which an investigational agent was administered within 14 days or 5-halflives, whichever is shorter, of starting CBX-250. Participants may continue with non-interventional follow-up from previous clinical studies.
  14. Any concurrent systemic treatment to prevent GVHD. Topical treatments for GVHD are permitted.
  15. Known allergy or sensitivity to study drug, including .
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    CBX-250

    subcutaneous CBX-250

    Drug: CBX-250

Interventions

  • DrugCBX-250

    subcutaneous CBX-250

06

What researchers measure

Primary outcomes

  1. To determine the safety, tolerability, RP2D, or MTD if different, and dosing regimen of CBX-250.

    Frequency and type of DLT

    Time frame: Until the end of study (approximately 24 months)

  2. To determine the safety, tolerability, RP2D, or MTD if different, and dosing regimen of CBX-250.

    Frequency, duration, and severity of TEAEs, TRAEs, AESIs, and SAEs

    Time frame: Until the end of study (approximately 24 months)

  3. To determine the safety, tolerability, RP2D, or MTD if different, and dosing regimen of CBX-250.

    Frequency and severity of CRS AEs

    Time frame: Until the end of study (approximately 24 months)

  4. To determine the safety, tolerability, RP2D, or MTD if different, and dosing regimen of CBX-250.

    Drug withdrawals, drug interruptions, or dose reductions due to adverse events

    Time frame: Until the end of study (approximately 24 months)

  5. To determine the safety, tolerability, RP2D, or MTD if different, and dosing regimen of CBX-250.

    Incidence/shifts of clinical laboratory abnormalities

    Time frame: Until the end of study (approximately 24 months)

Secondary outcomes

  1. AUC0-t (first dose and at steady state)

    Area under the plasma concentration-time curve from time 0 to time of last measurable concentration (AUC0-t) of CBX-250 and relevant metabolites

    Time frame: Approximately 1 year

  2. Cmax

    Maximum plasma concentration (Cmax) of CBX-250 and relevant metabolites

    Time frame: Approximately 1 year

  3. Tmax

    Time to observed maximum plasma concentration of CBX-250 and relevant metabolites

    Time frame: Approximately 1 year

  4. ADAs

    Incidence and severity of anti-drug antibodies

    Time frame: Approximately 1 year

  5. ORR

    To assess the overall response rate (ORR) of CBX-250

    Time frame: Approximately 1 year

  6. CR+CRh rate in AML

    To assess the complete remission (CR) and complete remission with partial hematologic recovery (CRh) rate

    Time frame: Approximately 1 year

  7. EFS

    To assess the event free survival (EFS) of CBX-250

    Time frame: Approximately 3 years

  8. OS

    To assess overall survival (OS) of CBX-250

    Time frame: Approximately 3 years

  9. DOR

    To assess the duration of response (DOR) of CBX-250

    Time frame: Approximately 3 years

  10. CRc rate in AML

    To assess the composite definition of complete remission (CRc) rate

    Time frame: Approximately 3 years

  11. Remission rate in HR-MDS

    Remission rate as defined by Zeidan 2023: CR, CR equivalent, partial remission (PR), CRL (CRuni and CRbi), CRh, Hematologic improvement (HI)

    Time frame: Approximately 1 year

  12. PFS

    To assess the progression free survival (PFS) of CBX-250

    Time frame: Approximately 3 years

  13. CR+CRh rate in HR-MDS

    CR+ CR equivalent+ CRL + CRh

    Time frame: Approximately 1 year

  14. Transfusion independence

    Any transfusion-free period lasting for at least 56 consecutive days, during which the participant is either on CBX-250 therapy or after cessation of CBX-250 therapy but prior to the start of new therapy

    Time frame: Approximately 3 years

  15. To assess the preliminary anti-leukemic activity of CBX-250 in participants with CMML

    Proportion of participants achieving complete response (CR), complete cytogenetic remission, partial response (PR), marrow response, and clinical benefit according to the 2015 International Consortium Proposal of Uniform Response Criteria for Myelodysplastic Syndromes (MDS)/Myeloproliferative Neoplasms (MPN).

    Time frame: Approximately 1 year.

  16. To assess the preliminary anti-CML activity of CBX-250 in participants with CML

    Proportion of participants achieving a ≥1-log10 reduction in BCR::ABL1 transcript levels from pre-treatment baseline at Week 12 (Day 169 ± 7 days), measured on the International Scale (IS) by centralized realtime quantitative PCR (RT-qPCR)

    Time frame: Approximately 1 year.

07

Study locations

11 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — It is anticipated that the results of this study may be presented at scientific meetings and/or published in a peer reviewed scientific or medical journal.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: One year after publication

Access criteria: Requests to be reviewed on an individual basis by Crossbow Therapeutics, Inc.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jan 2027, 18 months after the start.

Of 66 phase 1 interventional studies under Leukemia, Myelomonocytic, Chronic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 74. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2025
First posted
May 29, 2025
StartActual
Jul 16, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jun 2027
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06994676
Lead sponsor
Crossbow Therapeutics, Inc.
Responsible party
Sponsor
First posted
May 29, 2025
Start date
Jul 16, 2025
Primary completion
Jan 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Mar 16, 2026

Study contacts

Rachel Ghiraldi
Contact
rachel.ghiraldi@crossbowtx.com
857-301-6432
Briggs Morrison, MD
study chair · Crossbow Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion